Feedback / Questions
abelacimab (MAA868) - Novartis
Abelacimab: Regulatory submission for atrial fibrillation in 2027
(Novartis)
-
Oct 27, 2025 -
Q3 2025 Results
Filing
•
Atrial Fibrillation • Cardiovascular
https://www.novartis.com/sites/novartis_com/files/q3-2025-investor-presentation.pdf
Oct 27, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious